# CJC-1295 Ipamorelin Review (cjc-1295-ipamorelin.com)

> An independent editorial project that reads the peer-reviewed record on CJC-1295 and ipamorelin: the two receptors, the half-lives (5.8 to 8.1 days for CJC-1295 with DAC, 2 hours for ipamorelin), the doses used in published trials, the adverse events recorded, and the regulatory status. Every figure carries a DOI verified on CrossRef or an NCT number verified on ClinicalTrials.gov. Informational content, not medical advice. CJC-1295 and ipamorelin are investigational compounds, not approved by the FDA or the EMA.

## Main article
- [CJC-1295 ipamorelin: what the published studies actually show](https://cjc-1295-ipamorelin.com/): two molecules, why they are studied together, what the human trials measured, what is not known.

## Guides
- [CJC-1295 ipamorelin dosage](https://cjc-1295-ipamorelin.com/cjc-1295-ipamorelin-dosage/): every dose used in a published human study, in one table; no protocol.
- [CJC-1295 DAC vs no DAC](https://cjc-1295-ipamorelin.com/cjc-1295-dac-vs-no-dac/): half-life, pulsatility, injection frequency, which form belongs in a blend.
- [Mod GRF 1-29](https://cjc-1295-ipamorelin.com/mod-grf-1-29/): the linker-free CJC-1295, its four substitutions, the origin of the forum name.
- [Ipamorelin peptide](https://cjc-1295-ipamorelin.com/ipamorelin-peptide/): selectivity, 2-hour half-life, two phase 2 trials, 2023 FDA decision.
- [Ipamorelin side effects](https://cjc-1295-ipamorelin.com/ipamorelin-side-effects/): what was measured in swine, men and surgical patients.
- [Sermorelin vs CJC-1295 ipamorelin](https://cjc-1295-ipamorelin.com/sermorelin-vs-cjc-1295-ipamorelin/): three molecules compared on structure, receptor, half-life, data and status.
- [CJC-1295 ipamorelin for sale](https://cjc-1295-ipamorelin.com/cjc-1295-ipamorelin-for-sale/): the nine things a listing must state, price per milligram, legal frame.
- [CJC-1295 peptide](https://cjc-1295-ipamorelin.com/cjc-1295-peptide/): from the ConjuChem bench to two human trials and a terminated phase 2.
- [CJC-1295 ipamorelin vs tesamorelin](https://cjc-1295-ipamorelin.com/cjc-1295-ipamorelin-vs-tesamorelin/): the approved GHRH analogue against the two that were not.
- [What is CJC-1295 ipamorelin](https://cjc-1295-ipamorelin.com/what-is-cjc-1295-ipamorelin/): two receptors, GH pulsatility, the 1990 synergy experiment.
- [CJC-1295 ipamorelin Reddit questions](https://cjc-1295-ipamorelin.com/cjc-1295-ipamorelin-reddit/): seven recurring questions answered from the literature.
- [CJC-1295 side effects](https://cjc-1295-ipamorelin.com/cjc-1295-side-effects/): the human record, class effects, the IGF-1 and glucose questions.

## About
- [About and method](https://cjc-1295-ipamorelin.com/about/)
- [Editorial policy](https://cjc-1295-ipamorelin.com/editorial-policy/)
- Contact: editor@cjc-1295-ipamorelin.com

## Key facts
- CJC-1295 with DAC: 30-residue GHRH(1-29) analogue with four substitutions and an albumin-binding maleimide linker; human half-life 5.8 to 8.1 days (Teichman et al. 2006, doi:10.1210/jc.2005-1536).
- One week after a single 60 or 90 µg/kg dose, trough GH was 7.5-fold higher, mean GH 46 % higher, IGF-1 45 % higher, pulses unchanged (Ionescu and Frohman 2006, doi:10.1210/jc.2006-1702).
- Ipamorelin: pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, ghrelin-receptor agonist, no ACTH or cortisol release in swine at more than 200 times the ED50 (Raun et al. 1998, doi:10.1530/eje.0.1390552); terminal half-life 2 hours in men (Gobburu et al. 1999, doi:10.1023/A:1018955126402).
- No published human trial has administered CJC-1295 and ipamorelin together.
- The research-market blend holds the linker-free CJC-1295 (Mod GRF 1-29, 3,367.9 g/mol) and ipamorelin (711.9 g/mol) in equal mass; one documented source with per-lot certificates: https://oxpeptides.com/products/cjc-1295-ipamorelin (research use only).